+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Scorpius Holdings Inc (SCPX) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 47 Pages
  • October 2024
  • GlobalData
  • ID: 6012746
Scorpius Holdings Inc (SCPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Scorpius Holdings Inc (Scorpius), formerly known as NightHawk Biologics Inc, is a contract development and manufacturing organization (CDMO). It is focused on biologics manufacturing services. The company combines biomanufacturing expertise with advanced techniques in immunoassays and bioanalytical methods to produce cell- and gene-based therapies, as well as large molecule biologics. Scorpius offers services, including drug substance manufacturing, release testing, and process development, supporting clients from early preclinical stages to commercial launch and addressing the growing demands in biopharmaceutical manufacturing. It operates through a storage and testing facility in San Antonio, Texas, which features modular cleanroom space and single-use bioreactors. Scorpius is headquartered in Morrisville, North Carolina, the US.

Scorpius Holdings Inc Key Recent Developments

  • Sep 09, 2024: Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
  • Aug 26, 2024: Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, And Path Toward Positive Cash Flow
  • Aug 06, 2024: Scorpius Holdings Weighted-average Pipeline Surpasses $100 Million In Business Develop Opportunities Across Both Manufacturing Client And Government Sectors
  • Jul 24, 2024: Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Scorpius Holdings Inc - Key Facts
  • Scorpius Holdings Inc - Key Employees
  • Scorpius Holdings Inc - Key Employee Biographies
  • Scorpius Holdings Inc - Major Products and Services
  • Scorpius Holdings Inc - History
  • Scorpius Holdings Inc - Company Statement
  • Scorpius Holdings Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Scorpius Holdings Inc - Business Description
  • Scorpius Holdings Inc - Corporate Strategy
  • Scorpius Holdings Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Scorpius Holdings Inc - Strengths
  • Scorpius Holdings Inc - Weaknesses
  • Scorpius Holdings Inc - Opportunities
  • Scorpius Holdings Inc - Threats
  • Scorpius Holdings Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Scorpius Holdings Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 09, 2024: Scorpius Selected for Rapid Response Partnership Vehicle (RRPV) to Accelerate Medical Countermeasure Development in Support of BARDA
  • Aug 26, 2024: Scorpius Holdings CEO Provides Corporate Update; Highlights Expanding Sales Pipeline, Enhanced Manufacturing Capabilities, And Path Toward Positive Cash Flow
  • Aug 06, 2024: Scorpius Holdings Weighted-average Pipeline Surpasses $100 Million In Business Develop Opportunities Across Both Manufacturing Client And Government Sectors
  • Jul 24, 2024: Scorpius Holdings Set to Launch First Mammalian cGMP Campaign at San Antonio Facility in the 2024 3rd Quarter
  • Jul 18, 2024: Scorpius Holdings Successfully Executes First cGMP Microbial Batches at San Antonio Facility
  • Jun 30, 2024: Scorpius Holdings Achieves 16% Year-Over-Year Increase in Revenue for the Second Quarter of 2024
  • Jun 03, 2024: Scorpius Holdings and Beyond Imagination Announce Trailblazing Partnership to Utilize Autonomous AI-Powered Humanoid Robots for American Biomanufacturing
  • May 29, 2024: Scorpius Holdings Achieves 359% Year-Over-Year Increase in Revenue for the First Quarter of 2024
  • May 20, 2024: Scorpius Holdings Announces Major Expansion In San Antonio With New State-of-the-art Storage And Testing Facility
  • May 16, 2024: Scorpius Holdings Commends Congress on Bipartisan Legislative Action Aimed at Bolstering U.S. Biomanufacturing
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Scorpius Holdings Inc, Key Facts
  • Scorpius Holdings Inc, Key Employees
  • Scorpius Holdings Inc, Key Employee Biographies
  • Scorpius Holdings Inc, Major Products and Services
  • Scorpius Holdings Inc, History
  • Scorpius Holdings Inc, Subsidiaries
  • Scorpius Holdings Inc, Key Competitors
  • Scorpius Holdings Inc, Ratios based on current share price
  • Scorpius Holdings Inc, Annual Ratios
  • Scorpius Holdings Inc, Interim Ratios
  • Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Scorpius Holdings Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Scorpius Holdings Inc, Performance Chart (2019 - 2023)
  • Scorpius Holdings Inc, Ratio Charts
  • Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Scorpius Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Catalent Inc
  • Precigen Inc
  • Guided Therapeutics Inc
  • Lonza Group Ltd
  • Genentech USA Inc
  • Avid Bioservices Inc
  • WuXi AppTec Co Ltd